news
Update on Charles River’s collaboration with Moderna Therapeutics
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
List view / Grid view
Immuno-oncology
news
Macrophage raises £9 million & acquires immune-oncology technology
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
news
Targovax appoints of Øystein Soug as CEO
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014...
news
F-star expands immuno-oncology collaboration with CD Laboratory
14 July 2016 | By Victoria White, Digital Content Producer
F-star and the CD Laboratory seek to progress the understanding of the design, development and unique biology of antibody and antibody-based therapeutics...
news
Toulouse Oncopole Campus’ new research team to advance immuno-oncology research
2 June 2016 | By Victoria White, Digital Content Producer
The 'Toulouse Cancer Santé' Foundation and the Pierre Fabre have launched a new research team within the Cancer Research Centre of Toulouse...
news
Infinity presents new preclinical data for PI3K-gamma inhibitor, IPI-549
18 April 2016 | By Victoria White, Digital Content Producer
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma)...
news
BMS and Dana-Farber Cancer Institute enter I-O RPM collaboration
16 February 2016 | By Victoria White
As part of the I-O RPM programme, Bristol-Myers Squibb and Dana-Farber Cancer Institute will conduct a range of early phase clinical studies...
news
Adaptimmune and GSK expand cancer immunotherapy collaboration
3 February 2016 | By Victoria White
The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
news
MD Anderson and AbbVie join forces to fight cancer
26 January 2016 | By Victoria White
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in immuno-oncology...
news
Registration has now opened for Oxford Global’s 17th Annual Drug Discovery Leaders Summit
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
news
An interview with Elaine Pinheiro, Principal Scientist at MSD, speaker at the Advances in Immuno-oncology Congress, 12-13 May 2016, London, UK
13 January 2016 | By Oxford Global
Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment...
news
Novartis expands immuno-oncology pipeline with Surface Oncology alliance
11 January 2016 | By Victoria White
The agreement gives Novartis access to four preclinical programmes that target regulatory T-cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment...
news
Nanobiotix to explore NBTXR3 in immuno-oncology
5 January 2016 | By Victoria White
NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumours, in combination with radiotherapy...
news
LSP and Bristol-Myers Squibb team up for life sciences innovation
24 November 2015 | By Victoria White
The companies have said they will focus is on immuno-oncology, one of the hottest and most dynamic areas in biotechnology...
news
TIGIT identified as new target for immuno-oncology therapies
17 November 2015 | By Victoria White
Antibodies against TIGIT could improve the function of the DNAM-1 protein, thereby improving the ability of natural killer cells to destroy tumour cells...
